Nodexus operates in the biotechnology sector, focusing on the development and commercialization of an integrated platform designed for single-cell enrichment and analysis. The company's core product, the NX One platform, is a low-cost, compact system that simplifies the workflow for delivering enriched single cells from a variety of samples, including stem cells, transfected cell lines, cultured cell lines, dissociated tissue, and whole blood. This platform is particularly valuable for researchers who require accurate dispensing of individual live targets for further analyses.

Nodexus primarily serves academic and commercial research institutions, biotechnology companies, and pharmaceutical firms. The company operates in the life sciences market, which is characterized by a high demand for advanced cell analysis technologies. Nodexus's business model revolves around the sale of its NX One platform and associated consumables, generating revenue through both initial equipment sales and recurring purchases of consumable supplies.

The NX One platform offers highly sensitive cell screening, characterization, and active isolation capabilities, making it a versatile tool for various research applications. By providing a cost-effective and efficient solution for single-cell analysis, Nodexus aims to address the growing need for precise and reliable cell manipulation technologies in the research community.

Keywords: single-cell enrichment, biotechnology, NX One platform, cell analysis, stem cells, transfected cell lines, cultured cell lines, dissociated tissue, whole blood, life sciences.